Clinical Trials Logo

Post-ERCP Pancreatitis clinical trials

View clinical trials related to Post-ERCP Pancreatitis.

Filter by:

NCT ID: NCT01771419 Unknown status - Clinical trials for Post-ERCP Pancreatitis

Comparison Of Loop-Tip Wire Vs Tradictional Technique In The Cannulation Of The Common Bile Duct

Start date: October 2010
Phase: N/A
Study type: Interventional

Selective cannulation of common bile duct (CBD) by insertion of a guide-wire seems to be associated with fewer complications and post-ERCP (Endoscopic retrograde cholangiopancreatography) pancreatitis (PEP) rate than the conventional biliary tree access with cannulotome (CT-25 Cook Medical) with contrast injection even if results are conflicting. the aim of our study is to test a new guide-wire (loop-tip wire), with a loop in the tip, for the prevention of PEP and biliary tree access, in PEP high-risk patients.

NCT ID: NCT01717599 Completed - Clinical trials for Post ERCP Pancreatitis

Intramuscular Diclofenac in the Prevention of Post-ERCP Pancreatitis

Start date: August 29, 2012
Phase: N/A
Study type: Interventional

Pancreatitis is one of the major complications of ERCP. It has been shown that NSAIDs are potent inhibitors of phospholipase A2, activity which is increased in pancreatitis. The only one study with IM diclofenac showed reduction of post-ERCP pancreatitis without SOD (sphincter of Oddi dysfunction) by subgroup analysis in small study population. Therefore the investigators must need large scaled randomized control study including of SOD.

NCT ID: NCT00820612 Terminated - Clinical trials for Post-ERCP Pancreatitis

Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients

Start date: January 2009
Phase: Phase 4
Study type: Interventional

Pancreatitis (inflammation of the pancreas) is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP), a procedure for the diagnosis and treatment of disorders of the pancreas and bile duct. Preliminary data has shown that non-steroidal antiinflammatory drugs, when administered rectally, can reduce the risk of pancreatitis after ERCP. This study is intended to definitively determine whether rectally administered indomethacin (a non-steroidal antiinflammatory drug)is effective at preventing pancreatitis after ERCP.